08:53 AM EDT, 09/27/2024 (MT Newswires) -- Savara (SVRA) said Friday it has launched an Early Access Program for molgramostim, allowing physicians of eligible patients with autoimmune pulmonary alveolar proteinosis to request the investigational inhalation solution in select regions where it is not yet commercially available.

The program has been reviewed and allowed to proceed by the US Food and Drug Administration, and is expected to expand through 2026, Savara said, adding it aims to complete a Biologics License Application submission for molgramostim as a treatment for aPAP to the FDA in H1 2025.

Shares of the company were up nearly 1% in recent Friday premarket activity.

Price: 4.2800, Change: +0.04, Percent Change: +0.94